EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Overcoming barriers to off-patent drug repurposing: a lifecycle-based policy solutions

Mario Garcia-Diaz, David Epstein, Jaime Espin

Frontiers in Pharmacology · 24.10.2025 · 16

DOI: 10.3389/fphar.2025.1670845 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 24.10.2025. Verfasst von Mario Garcia-Diaz und 2 weiteren Autor:innen. Beteiligte Einrichtung: Andalusian School of Public Health, Granada, Spain. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: HORIZON EUROPE Framework Programme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Drug repurposing leverages existing medicines to reduce time and costs for exploring new therapeutic indications. However, off-patent medicines do not provide enough private incentives for investment, and prescribing by active ingredient can be a major barrier. Academics and non-profit sponsors also face regulatory barriers.

Methods

This study combined a structured literature review with a questionnaire completed by 25 drug repurposing experts to identify key challenges and policy solutions across the full lifecycle of off-patent drug repurposing.

Results

Public funding is generally available for the early-stage research, where opportunities often arise from off-label uses and real-world evidence. However, limited support for confirmatory clinical trials, combined with the predominance of academics and non-profit sponsors lacking regulatory objectives, reduces the likelihood of successful authorisation to below 30%. Policy solutions include prioritising research into rare diseases and other conditions with unmet health needs, and call for a more prominent role of governments in public investment and in reinforcement of public–private partnerships. Substitution in community pharmacies remains a major challenge, which may be addressed through indication-based differentiation and enhanced dispensing controls. Some innovative public intervention mechanisms, such as Social Impact Bonds and the InterVentional PharmacoEconomics proposal, offer potential, although real-world experience is still limited.

Conclusion

Off-patent drug repurposing faces persistent financial and regulatory barriers that require a central role from academics and non-profit sponsors, supported by governmental engagement throughout the lifecycle. Although steps have been taken in recent years, efforts remain insufficient, and structural and political barriers continue to hinder broader implementation.

Schlagwörter

Stichwörter der Autor:innen

BarriersDrug repurposingLifecycleacademic researchnon-profit organisationsoff-patent medicinespolicy solutionspublic Funding

Autor:innen und Institutionen

  • Andalusian School of Public Health, Granada, Spain.
  • Faculty of Economics and Business, University of Granada, Granada, Spain.
  • Department of Applied Economics, University of Granada, Granada, Spain.
  • Instituto de Investigación Biosanitaria ibs, Granada, Spain.
  • CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain.

Förderung

  • HORIZON EUROPE Framework Programme

Zitieren

APA

Garcia-Diaz, M., Epstein, D., & Espin, J. (2025). Overcoming barriers to off-patent drug repurposing: a lifecycle-based policy solutions. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1670845

Vancouver

Garcia-Diaz M, Epstein D, Espin J. Overcoming barriers to off-patent drug repurposing: a lifecycle-based policy solutions. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1670845

BibTeX
@article{GarciaDiaz2025,
  author = {Garcia-Diaz, Mario and Epstein, David and Espin, Jaime},
  title = {Overcoming barriers to off-patent drug repurposing: a lifecycle-based policy solutions},
  journal = {Frontiers in Pharmacology},
  year = {2025},
  volume = {16},
  doi = {10.3389/fphar.2025.1670845}
}
Kostenlos starten →